A neutralizing nanobody-based liquid-phase blocking ELISA to assess the protective potency of Senecavirus A vaccine
Applied Microbiology and Biotechnology · 2025
DOI: 10.1007/s00253-025-13492-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, 2025. Verfasst von Suyu Mu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Insti…. Hauptthemen laut MEDLINE: Viral Vaccines, Antibodies, Neutralizing, Picornaviridae, Picornaviridae Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key R&D Program of Ningxia province, The Major Science and Technology Project of Gansu Province, Hongsheng Biological Open Research Project.
Abstract (Originalsprache)
Senecavirus A (SVA) causes swine blister diseases in the crown of hooves, abortion syndrome, and increased mortality rates in piglets. Vaccination is the best defense against SVA infection. However, evaluations of the efficacy of SVA vaccines currently rely on challenging pigs with SVA, which is time-consuming, labor-intensive, and inconsistent with animal welfare mandates. To establish a replacement for the virus neutralization test (VNT) and SVA challenge tests, we developed a liquid-phase blocking enzyme-linked immunosorbent assay (nbLPB-ELISA) based on V1-VHH as the coating antibody (Ab) and biotinylated V1-VHH as the detection Ab. Under optimized conditions, the VNT and nbLPB-ELISA results were strongly correlated (Pearson R2 = 0.84; p < 0.00001). Analysis of the LBP-ELISA and vaccine protection rate revealed that neutralizing Ab titers greater than 256 provided 100% protection, while titers of 64 and 128 offered 57.1% and 70% protection, respectively. The nbLPB-ELISA is a rapid, simple, safe, and cost-effective method of detecting SVA as a replacement for the SVA VNT and vaccine-challenge assays. KEY POINTS: • We evaluated a specific, high-affinity, and neutralizing nanobody-targeting SVA. • The developed nbLPB-ELISA can replace viral neutralization tests. • The nbLPB-ELISA is suitable to evaluate protective immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730046, China.
- School of Tropical Agriculture and Forestry, Hainan University, Haikou, 570228, Hainan Province, China.
- State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730046, China…
Förderung
- Key R&D Program of Ningxia province
- The Major Science and Technology Project of Gansu Province
- Hongsheng Biological Open Research Project
- Gansu Postdoctoral Science Foundation
- China Postdoctoral Science Foundation
- Technology innovation guidance program of Gansu Province
Zitieren
APA
Mu, S., Pan, S., Dong, H., Wu, J., Zhang, Y., Yin, S., Wang, J., Wei, T., Wen, X., Guo, H., & Sun, S. (2025). A neutralizing nanobody-based liquid-phase blocking ELISA to assess the protective potency of Senecavirus A vaccine. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-025-13492-4
Vancouver
Mu S, Pan S, Dong H, Wu J, Zhang Y, Yin S, et al. A neutralizing nanobody-based liquid-phase blocking ELISA to assess the protective potency of Senecavirus A vaccine. Applied Microbiology and Biotechnology. 2025. doi:10.1007/s00253-025-13492-4
BibTeX
@article{Mu2025,
author = {Mu, Suyu and Pan, Songjia and Dong, Hu and Wu, Jinen and Zhang, Yun and Yin, Shuanghui and Wang, Jianing and Wei, Tian and Wen, Xiaobo and Guo, Huichen and Sun, Shiqi},
title = {A neutralizing nanobody-based liquid-phase blocking ELISA to assess the protective potency of Senecavirus A vaccine},
journal = {Applied Microbiology and Biotechnology},
year = {2025},
doi = {10.1007/s00253-025-13492-4}
}
EUVIMED